Swipe om te navigeren naar een ander hoofdstuk
Worldwide, breast cancer is the most frequently diagnosed cancer. In the Netherlands, 1 in 8 women will be diagnosed with breast cancer at some point during life, corresponding with a cumulative life time risk of 12–13 %. Approximately 75 % of the newly diagnosed breast cancer patients are aged 50 or older. Approximately 7 % are less than 40 years. These young women with breast cancer comprise a particular subset due to the often more aggressive biology of their tumours as well as their unique psychosocial concerns. They are at a higher risk of carrying a high-risk allele for hereditary breast cancer and will be offered counselling by a clinical geneticist irrespective of their family history. Young women, who are often advised to have systemic chemotherapy, can be confronted with treatment-related infertility and/or premature ovarian failure. Therefore counselling by gynaecologists, in close collaboration with medical oncologists, is immediately offered after diagnosis if they want to have children. Young women can suffer various other long-term physical and mental side effects of oncological treatment. Problems related to premature ovarian failure include menopausal symptoms such as hot flushes, genitourinary problems, psychological and psychosexual difficulties, and accelerated loss of bone mineral density. Premature menopause may contribute to increased cardiovascular morbidity.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Atisha DM, Rushing CN, Samsa GP, Locklear TD, Cox CE, Shelley Hwang E, Zenn MR, Pusic AL. A national snapshot of satisfaction with breast cancer procedures. Ann Surg Oncol. 2015;22(2):361–9. CrossRef
Amant F, Minckwitz G von, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Calsteren K van, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Calster B van, Loibl S. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013 Jul 10;31(20):2532–9. CrossRef
Cardoso F, Veer LJ van’t, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, Hoeven JM van der, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M. (Mindact Investigators) 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016 Aug 25;375:717–29. CrossRef
Collaborative Group on Hormonal Factors in Breast C. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.
Donker M, Tienhoven G van, Straver ME, Meijnen P, Velde CJ van de, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, Mijle HC van der, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, Graaf PW de, Dalen T van, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10. CrossRef
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41. CrossRef
Lambe M, Hsieh CC, Chan HW, Ekbom A, Trichopoulos D, Adami HO. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat. 1996;38(3):305–11. CrossRef
Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 2015;1(5):611–21. CrossRef
Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, Wasser MN, Bergers E, Kok T, Muller SH, Peterse H, Tollenaar RA, Hoogerbrugge N, Meijer S, Bartels CC, Seynaeve C, Hooning MJ, Kriege M, Schmitz PI, Oosterwijk JC, Koning HJ de, Rutgers EJ, Klijn JG. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC screening study. J Clin Oncol. 2010 Dec 20;28(36):5265–73. CrossRef
Scott NW, Fayers PM, Aaronson NK, Bottomley A, Graeff A de, Groenvold M, et al. EORTC QLQ-C30 reference values [PDF]2008 [cited 2017 26-07-2017]. Available from: http://groups.eortc.be/qol/sites/default/files/img/newsletter/reference_values_manual2008.pdf.
Sobin LH, Gospodarowicz M, Wittekind C, editor. TNM classification of malignant tumors. 7th ed. New York: John Wiley & Sons, Inc.; 2009.
- Breast cancer
Dr Lindy A. M. Santegoets
PhD Linetta B. Koppert
- Bohn Stafleu van Loghum